PFE Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 Mai 2024 @ 22:01):

Stats
Tagesvolumen	54.12M
Durchschnittsvolumen	40.98M
Marktkapitalisierung	156.42B
EPS	$0 ( 2024-05-01 )
Nächstes Ertragsdatum	( $0 ) 2024-07-30
Last Dividend	$0.410 ( 2023-11-09 )
Next Dividend	$0 ( N/A )
P/E	-554.00
ATR14	$0.0230 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Damico Jennifer B.	Buy	55	Phantom Stock Units SSP
2024-04-30	Bourla Albert	Buy	20	Phantom Stock Units SSP
2024-04-25	Quincey James	Buy	8 116	Phantom Stock Units
2024-04-25	Smith James C	Buy	8 116	Phantom Stock Units
2024-04-25	Nora Johnson Suzanne M	Buy	8 116	Phantom Stock Units

INSIDER POWER
70.76
Last 100 transactions
Buy: 4 322 762 \| Sell: 745 543

Volumen Korrelation

Lang: -0.17 (neutral)

Kurz: -0.42 (neutral)

Signal:(44.375) Neutral

Pfizer Inc Korrelation

10 Am meisten positiv korreliert
PCQ	0.969
ZME	0.962
CHGG	0.951
RSF	0.947
GDMA	0.946
TPL	0.941
CALX	0.939
EVTL	0.937
PCK	0.936
K	0.93

10 Am meisten negativ korreliert
WWW	-0.954
HCI	-0.953
NGL-PB	-0.95
FSNB	-0.949
LOCC	-0.949
LHC	-0.948
VNT	-0.947
CRH	-0.945
FTAI	-0.942
JMP	-0.94

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Pfizer Inc Korrelation - Währung/Rohstoff

-0.15
( neutral )

-0.29
( neutral )

0.00
( neutral )

-0.10
( neutral )

0.06
( neutral )

-0.23
( neutral )

Pfizer Inc Finanzdaten

Annual	2023
Umsatz:	$58.50B
Bruttogewinn:	$29.28B (50.06 %)
EPS:	$0.380

FY	2023
Umsatz:	$58.50B
Bruttogewinn:	$29.28B (50.06 %)
EPS:	$0.380

FY	2022
Umsatz:	$100.33B
Bruttogewinn:	$65.99B (65.77 %)
EPS:	$5.59

FY	2021
Umsatz:	$81.29B
Bruttogewinn:	$50.47B (62.08 %)
EPS:	$3.92

Financial Reports:

No articles found.

Pfizer Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.400 (N/A)	$0.400 (N/A)	$0.410 (N/A)	$0.410 (N/A)	$0.410 (N/A)	$0.410 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Pfizer Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 6.10 - average (70.40%) | Divividend Growth Potential Score: 4.01 - Stable (19.84%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00316	1972-08-29
Last Dividend	$0.410	2023-11-09
Next Dividend	$0	N/A
Payout Date	2023-12-04
Next Payout Date	N/A
# dividends	206	--
Total Paid Out	$26.05	--
Avg. Dividend % Per Year	2.24%	--
Score	4.91	--
Div. Sustainability Score	6.10
Div.Growth Potential Score	4.01
Div. Directional Score	5.06	--

Next Divdend (Est)
(2024-07-01)

$0.413 Estimate 39.90 %

Dividend Stability

0.80 Good

Dividend Score

4.91

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1972	$0.00731	0.90%
1973	$0.0138	1.60%
1974	$0.0156	1.83%
1975	$0.0160	2.52%
1976	$0.0170	3.03%
1977	$0.0196	3.44%
1978	$0.0231	4.27%
1979	$0.0261	3.98%
1980	$0.0285	3.84%
1981	$0.0316	3.01%
1982	$0.0364	3.50%
1983	$0.0460	3.43%
1984	$0.0524	3.66%
1985	$0.0584	3.65%
1986	$0.0648	3.27%
1987	$0.0712	2.91%
1988	$0.0792	4.13%
1989	$0.0868	3.81%
1990	$0.0948	3.37%
1991	$0.104	3.29%
1992	$0.117	1.77%
1993	$0.133	2.32%
1994	$0.149	2.77%
1995	$0.164	2.74%
1996	$0.190	1.93%
1997	$0.215	1.66%
1998	$0.240	1.00%
1999	$0.291	0.75%
2000	$0.342	1.13%
2001	$0.416	0.95%
2002	$0.492	1.30%
2003	$0.568	1.90%
2004	$0.644	1.91%
2005	$0.720	2.87%
2006	$0.912	4.04%
2007	$1.100	4.41%
2008	$1.216	5.59%
2009	$0.760	4.39%
2010	$0.684	3.81%
2011	$0.760	4.53%
2012	$0.836	4.01%
2013	$0.912	3.71%
2014	$0.988	3.42%
2015	$1.064	3.58%
2016	$1.140	3.76%
2017	$1.216	3.88%
2018	$1.292	3.74%
2019	$1.368	3.33%
2020	$1.444	3.89%
2021	$1.560	4.24%
2022	$1.600	2.82%
2023	$1.640	3.20%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0364	1.500	9.27	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00941	1.200	9.69	10.00	[0 - 0.3]
returnOnEquityTTM	0.0221	1.500	-0.866	-1.298	[0.1 - 1]
payoutRatioTTM	4.34	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0.907	0.800	-0.467	-0.373	[1 - 3]
quickRatioTTM	0.499	0.800	-1.768	-1.415	[0.8 - 2.5]
cashRatioTTM	0.0597	1.500	-0.779	-1.169	[0.2 - 2]
debtRatioTTM	0.320	-1.500	4.67	-7.01	[0 - 0.6]
interestCoverageTTM	1.631	1.000	-0.507	-0.507	[3 - 30]
operatingCashFlowPerShareTTM	1.541	2.00	9.49	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.849	2.00	9.58	10.00	[0 - 20]
debtEquityRatioTTM	0.814	-1.500	6.75	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.490	1.000	5.17	5.17	[0.2 - 0.8]
operatingProfitMarginTTM	0.0616	1.000	-0.768	-0.768	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.120	1.000	-0.444	-0.444	[0.2 - 2]
assetTurnoverTTM	0.258	0.800	-1.612	-1.289	[0.5 - 2]
Total Score				6.10

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	73.37	1.000	2.69	0	[1 - 100]
returnOnEquityTTM	0.0221	2.50	-0.556	-1.298	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.849	2.00	9.72	10.00	[0 - 30]
dividendYielPercentageTTM	5.96	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.541	2.00	9.49	10.00	[0 - 30]
payoutRatioTTM	4.34	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	-1.568	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.149	1.000	8.78	0	[0.1 - 0.5]
Total Score				4.01

Pfizer Inc

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.